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Abstract: Infection by oncogenic human papillomavirus (HPV) is the principle cause of cervical 
cancer and other anogenital cancers. The majority of cervical cancer cases occur in low- and middle-
income countries (LMIC). Prophylactic vaccines exist to combat HPV infection but accessibility to 
these in LMIC is limited. Alternative preventative measures against HPV infection are therefore also 
needed to control cervical cancer risk. HPV employs multiple mechanisms to evade the host 
immune response. Therefore, an approach to promote HPV recognition by the immune system can 
reduce infection. Surfactant proteins A and D (SP-A and SP-D) are highly effective innate opsonins 
of pathogens. Their function is primarily understood in the lung, but they are also expressed at other 
sites of the body, including the female reproductive tract (FRT). We hypothesized that raised levels 
of SP-A and/or SP-D may enhance immune recognition of HPV and reduce infection. Co-
immunoprecipitation and flow cytometry experiments showed that purified human SP-A protein 
directly bound HPV16 pseudovirions (HPV16-PsVs), and the resulting HPV16-PsVs/SP-A complex 
enhanced uptake of HPV16-PsVs by RAW264.7 murine macrophages. In contrast, a recombinant 
fragment of human SP-D bound HPV16-PsVs weakly and had no effect on viral uptake. To assess if 
SP-A modulates HPV16-PsVs infection in vivo, a murine cervicovaginal challenge model was 
applied. Surprisingly, neither naïve nor C57BL/6 mice challenged with HPV16-PsVs expressed SP-
A in the FRT. However, pre-incubation of HPV16-PsVs with purified human SP-A at a 1:10 (w/w) 
ratio significantly reduced the level of HPV16-PsV infection. When isolated cells from FRTs of naïve 
C57BL/6 mice were incubated with HPV16-PsVs and stained for selected innate immune cell 
populations by flow cytometry, significant increases in HPV16-PsVs uptake by eosinophils, 
neutrophils, monocytes, and macrophages were observed over time using SP-A-pre-adsorbed 
virions compared to control particles. This study is the first to describe a biochemical and functional 
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association of HPV16 virions with the innate immune molecule SP-A. We show that SP-A impairs 
HPV16-PsVs infection and propose that SP-A is a potential candidate for use in topical microbicides 
which provide protection against new HPV infections. 
Keywords: human papillomavirus (HPV); surfactant proteins A and D (SP-A and SP-D); murine 
cervicovaginal challenge model; innate immune cells; opsonins 
 
1. Introduction 
Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. 
According to their association with malignancy, HPVs are broadly divided into high-risk and low-
risk types. High-risk HPVs represent one of the seven groups of oncogenic viruses known to date 
which have been recognized to be consistently associated with various types of human cancer [1], 
with HPV types 16 and 18 being the most common oncogenic HPV types world-wide and the major 
cause of cervical cancer [2]. This disease is substantially more prevalent in low-and middle-income 
countries (LMIC), and is the leading cause of female cancer-associated deaths in Sub-Saharan Africa, 
not least due to the concomitant Human immunodeficiency virus (HIV)/acquired immunodeficiency 
syndrome (AIDS) epidemic in this region [3–5]. Although highly efficient prophylactic vaccines 
against the most common high-risk HPV types exist, roll out to LMIC has been severely limited due 
to cost, difficulties in reaching the target population, cultural challenges, and the necessity for a cold 
chain [6]. Therefore, alternative means to protect against sexually transmitted HPVs are much 
needed. For example, the naturally-derived sulphated polysaccharide carrageenan has been shown 
to inhibit early HPV infection by blocking viral attachment to cells [7,8]. This inhibitory effect was 
supported by clinical trials demonstrating a negative association of HPV infection with the vaginal 
microbicide Carraguard [9]. However, while carrageenan also showed protection against herpes 
simplex virus 2 (HSV-2) [10], it did not prevent against vaginal transmission of HIV [11]. 
Another alternative approach for prevention of HPV infection is the activation of the innate 
immune response leading to enhanced recognition and elimination of the virus before infection of its 
target cells. Most HPV infections are transient with clearance mediated by cell-mediated immune 
mechanisms usually within 6–12 months, leaving the infected individual partly or fully immune to 
that particular HPV type. However, failure to develop effective immune responses and depending 
on HPV type, viral load, immune status of the host and/or ongoing HPV exposure, the virus can reach 
the squamous epithelial cells where it remains effectively ‘hidden’ from the host immune system 
resulting in persistent infection and an increased probability of progression into invasive cancers [12]. 
Indeed, HPV employs several mechanisms to effectively evade the innate immune response thereby 
delaying the activation of adaptive immunity as the virus is not cytolytic, there is no viremia, no 
inflammation and no danger signals to alert the immune system [12].  
Surfactant proteins (SPs), particularly SP-A and SP-D, are innate immune molecules which 
enhance pathogen recognition and phagocytosis by opsinization [13]. They were originally identified 
in the lung as components of pulmonary surfactant involved in maintaining lung homeostasis and 
protecting it from infection. Both proteins are therefore best studied for their roles in the control of 
various respiratory pathogens, including influenza A virus, respiratory syncytial virus, 
Mycobacterium tuberculosis, Aspergillus fumigatis, Pseudomonas aeruginosa, Haemophilus influenza, and 
Nippostrongylus brasiliensis [14–22]. However, their expression at various non-pulmonary sites, 
including the female reproductive tract (FRT), suggests additional yet largely unexplored roles for 
pathogen control in these compartments [23].  
SP-A and SP-D are members of the collectins family. They are large hydrophilic soluble proteins 
that act as collagenous C-type lectin pattern recognition receptors, generally in a calcium dependent 
manner [24]. Their primary structure is composed of an N-terminal non-collagenous domain which 
can form inter-subunit disulphide bonds, followed by a collagenous region of Gly-X-Y repeats, a 
helical neck domain and a globular C-terminal carbohydrate recognition domain (CRD). Trimers are 
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formed by spontaneous self-assembly of such monomeric units which further form higher-order 
bunch-like SP-A octadecamers and cruciform SP-D dodecamers, respectively [25]. Despite their 
similar domain architectures, SP-A and SP-D differ in their ligand binding specificities. SP-A 
preferentially binds to mannose, fucose, and lipid ligands on the surface of incoming pathogens, 
while SP-D mostly binds maltose, inositol, glucose and more complex carbohydrates [26,27]. Both SP-
A and SP-D have very low affinities to galactose and sialic acid (sugars that often form the terminals 
of carbohydrates on animal cells) which is important for distinguishing self from non-self [27]. SPs 
recognition and binding of their specific ligands often occurs via their CRDs and triggers various 
immune responses, including opsonization and enhanced phagocytosis, regulating macrophage 
function and inflammation, and killing [27]. In the human FRT, SP-A has been detected in the 
myometrium, vaginal epithelium, and vaginal lavage fluid, while SP-D was found in the cervix, 
vagina, and endometrium [28–30]. It has been suggested that both SPs play protective roles during 
pregnancy [31] as well as contribute to innate immune defences against sexually transmitted 
pathogens [32–34].  
In an attempt to identify novel molecules that enhance immune recognition of oncogenic HPV, 
we herein demonstrate for the first time that SP-A but not SP-D binds directly to HPV16-PsVs and 
increases viral uptake into innate immune cells, thereby attenuating overall cervicovaginal infection 
in a mouse model. 
2. Results 
2.1. Binding of HPV16-PsVs to SP-A but not SP-D Results in Increased Viral Uptake by RAW264.7 
Macrophages.  
In an attempt to identify molecules that enhance innate immune recognition of oncogenic HPV 
thereby preventing initial infection, we studied the role of surfactant proteins A and D on HPV16 
pseudovirion (HPV16-PsVs) infection. Co-immunoprecipitation experiments of purified human SP-
A or recombinant SP-D together with HPV16-PsVs using antibodies against SP-A, SP-D and HPV16 
L1 (CamVir) revealed a direct biochemical association between the virions and SP-A and to a much 
lesser degree with recombinant SP-D: while HPV16-PsVs could be detected in the eluate (but not the 
FT fraction) when the HPV/SP-A input was immunoprecipitated with an SP-A antibody (Figure 1A), 
the majority of the virions derived from the HPV/SP-D input were detected in the FT fraction and 
very little in the eluate when immunoprecipitated with an SP-D antibody (Figure 1B). To test whether 
this physical interaction between SP-A and HPV16-PsVs had any functional consequences on 
immune cell recognition, virus internalization assays using the murine macrophage cell line 
RAW264.7 were performed. As presented in Figure 1C, pre-incubation of the viral particles with SP-
A, but not with SP-D, significantly enhanced their uptake by the macrophages (Figure 1C). We also 
determined downstream reporter gene activity 48h post-infection as a measure of successful 
infection, i.e., the transcription of the firefly luciferase plasmid encapsidated in the viral particle 
representing the pseudogenome. It was noted that the infectivity of RAW264.7 macrophages by 
HPV16-PsVs compared to the human cervical cancer cell line HeLa cells was extremely low 
(approximately 15,000-fold less, Figure 1D). However, when HPV16-PsVs were pre-incubated with 
SP-A, luciferase activity measured in RAW264.7 cells increased by approximately three-fold, but had 
no effect on HeLa cell infection (Figure 1D). We therefore focused our experiments on viral immune 
recognition and uptake and hypothesized that macrophages may prevent infection by effectively 
killing most of the internalized virus which may be facilitated by SP-A. This is supported by the 
general assumption that HPV has a very strict tissue tropism in vivo and exclusively infects basal 
epithelial cells [35]. To our knowledge, macrophages are not known to be infected by HPV. 
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Figure 1. Binding of HPV16-PsVs to SP-A but not SP-D results in increased viral uptake by RAW264.7 
macrophages but not by HeLa cervical epithelial cells. (A,B) Co-immunoprecipitation experiments 
displaying the input, flow through (FT) and eluate samples of HPV16-PsVs incubated with (A) SP-A 
and (B) SP-D. Complexes were incubated for 1h at 4 °C, followed by precipitations with either anti-
HPV16-L1 (CamVir), anti-SP-A or anti-SP-D antibodies. Western blots were performed using the 
CamVir antibody to detect the presence of HPV16-L1. (C) RAW264.7 cells were infected with 
fluorescently labelled HPV16-PsVs (pre-absorbed with recombinant proteins where indicated) for 1 
h at 37 °C. Cells were washed extensively and lifted with trypsin/EDTA to remove surface-bound 
virions and subjected to flow cytometry to quantify viral internalization. Experiments were 
performed in triplicates, quantified by quadrant analysis of the dot blots of three independent 
experiments and presented as x-fold increase relative to the mean fluorescence intensity of cells 
infected with untreated HPV16-PsVs which was set as 1. Significances were calculated by means of 
one-way ANOVA and Tukey post-hoc tests. *** indicates statistical significance between uptake of 
HPV16-PsVs in the presence of SP-A as compared to the other tested conditions (*** = p < 0.001). (D) 
RAW264.7 and HeLa were infected with HPV16-PsVs encapsidating the firefly luciferase reporter 
plasmid pGL3-control for 48 h. Where indicated, the viral particles were pre-absorbed with purified 
SP-A protein (or BSA control) before infection. Firefly luciferase activities in the cell lysates as a 
measure for successful infection is presented as Relative Light Units relative to RAW264.7 cells 
infected with untreated HPV16-PsVs which was set as 1. Bars in C and D depict mean values, with 
error bars showing SEM. Surfactant proteins A and D: SP-A, SP-D. 
2.2. SP-A-Mediated HPV16-PsVs Uptake by RAW264.7 Macrophages is Calcium-Dependent, but not 
Dependent on the Lectin-Binding Domain.  
SP-A is known to recognize and bind specific carbohydrate moieties on the surface of 
microorganisms via their CRD. For example, it has been shown that SP-A targets the HIV envelope 
glycoprotein gp120 in a calcium-dependent manner, which could be inhibited by mannose and EDTA 
[32]. Although HPV is a non-enveloped virus not known to contain glycosylated proteins in its 
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capsid, we set out to test whether this mode of interaction was also applicable to HPV16-PsVs. We 
therefore conducted further HPV16-PsVs internalization experiments with SP-A-pre-incubated 
virions in the absence or presence of CaCl2 or mannose. As presented in Figure 2A, viral uptake by 
RAW264.7 macrophages was strongly enhanced with increasing CaCl2 concentrations, an effect that 
was completely abolished in the presence of EDTA. However, viral uptake was not affected by 
mannose (Figure 2B) which is known to act as a competitive CRD inhibitor [36]. We therefore 
conclude that SP-A, as a typical C-type lectin, requires calcium for binding and functionality, while 
this does not involve its lectin-binding domain itself.  
 
Figure 2. SP-A-mediated HPV16-PsVs uptake by RAW264.7 macrophages is calcium-dependent, but 
not dependent on the CRD. AF488-labelled HPV16-PsVs were incubated in the presence of 10-fold 
(w/w) excess SP-A and (A) with or without 2 mM or 5 mM calcium chloride in the presence or absence 
of 10 mM EDTA as indicated, or (B) various concentrations of mannose. Shown are summaries of 
viral internalisation experiments as determined by FACS as described in Figure 1C. Fluorescent 
readings are displayed relative to HPV16-PsVs internalisation in the presence of SP-A only which was 
set as 1. Quantification of three independent experiments performed in duplicate are shown. 
Statistical significance was determined using one-way ANOVA and Tukey post-hoc tests. *= p < 0.05, 
** = p < 0.01, *** = p < 0.001. Bars depict mean values, with error bars showing SEM. 
2.3. Cervicovaginal Challenge with HPV16-PsVs does not Alter SP-A Expression in the Murine FRT.  
While the in vitro findings described above suggest a role of SP-A in enhancing immune 
recognition of incoming HPV16-PsVs, the natural HPV infection environment in the genital tract is 
very complex as several diverse cell types are potentially involved in immune responses upon viral 
challenge, including local epithelial cells and recruited inflammatory cells. We therefore studied the 
impact of SP-A on HPV16-PsVs infection in a murine model which particularly reflects the early 
events in infection [8,37] (Figure 3A).  
To assess whether the level of SP-A in the murine FRT changes upon HPV challenge, we 
performed several gene and protein expression assays at 24 h and 72 h post infection. While SP-A is 
known to be expressed in the human FRT [30], to our surprise no SP-A was detected in either the 
vaginal lavage fluid or homogenized FRTs of naïve C57BL/6 mice (Figure 3B). Moreover, exposure 
to HPV16-PsVs neither induced SP-A gene expression in the murine FRT 24 h post infection (Figure 
3C,D) nor did it increase detectable SP-A protein 24 h or 72 h post infection in the murine FRT or 
vaginal lavage fluid, respectively (Figure 3E,F). Therefore, infection with HPV16-PsVs does not affect 
endogenous SP-A expression in the FRT of C57BL/6 mice. 
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Figure 3. Infection of C57BL/6 mice with HPV16-PsVs does not alter SP-A expression. (A) Mouse 
model for HPV16-PsVs infection using C57BL/6 mice, adapted from Roberts et al., 2007 [8,37]. Briefly, 
6–10 weeks old female wildtype C57/BL6 mice were injected with 2 mg Depo-Provera (s.c.) for 4 days, 
and then pre-treated with 25 µl 4% N-9 in 3% CMC i.vag. for 6 h prior to HPV16-PsVs infection. Six 
mice per group were i.vag. infected with 3 µg or 1 µg viral particles encapsidating the reporter gene 
firefly luciferase (pGL3-control) or Gaussia luciferase (pGLuc), respectively. After 1–3 days, tissues 
were harvested for analysis. (B) Western blot assessing SP-A expression in lung, bronchoalveolar 
lavage fluid (BAL), female reproductive tract (FRT) tissue, and vaginal lavage (vag. lavage) fluid of 
naïve wildtype C57BL/6 mice. 20 µg of each sample was loaded per lane, while 0. 5 µg of purified 
human SP-A protein was loaded as control. No endogenous SP-A was detected in the FRT of naïve 
mice. (C) Four mice per group were i.vag. infected with 3 µg HPV16-PsVs encapsidating the pGL3-
control reporter plasmid. Genital tract tissue was harvested 24 h later and RNA extracted for gene 
expression analysis to confirm successful infection. (D) RNA from (C) was assessed for SP-A 
expression, with lung RNA used as positive control. Gapdh was used as a reference gene. (E) Four 
mice per group were i.vag. infected with 3 µg HPV16-PsVs. Vaginal lavages were performed 24 h and 
72 h p.i. and assessed by Western Blot for the presence of SP-A. 20 µg of each sample was loaded per 
lane, while 0.5 µg purified human SP-A protein was loaded as control. * Loading control corresponds 
to a 45 kDa cellular protein that cross-reacts with the CamVir primary antibody [38]. (F) Four mice 
per group were i.vag. infected with 3 µg HPV16-PsVs and genital tract tissue was harvested 24 h or 
72 h p.i., homogenised and assessed by Western blot for the presence of SP-A as described in (E). 
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2.4. HPV16-PsVs Complexed with SP-A Reduces Infection by Increasing Macrophage Recruitment and 
Recognition by Innate Immune Cells.  
Since SP-A was not detectable in the FRT of both naïve and HPV16-challenged C57BL/6 mice, 
we asked whether artificial supplementation with exogenous SP-A had an effect on HPV infection. 
As shown in Figure 4A, pre-incubation of HPV16-PsVs with purified SP-A at a 1:10 (w/w) ratio 
decreased the level of infection over time with significant reduction seen 72 h post infection.  
To determine whether the presence of SP-A elicited an immune response that led to the observed 
overall decrease in HPV16-PsVs infection, C57BL/6 mice were challenged with SP-A-complexed 
AF488-conjugated HPV16-PsVs for 2 h, followed by FRT dissection and preparation for macrophage 
staining and visualization by confocal microscopy. Representative images are shown in Figure 4B 
(lower panel) which demonstrate macrophage recruitment into the basal epithelium and to the site 
of infection in the presence of SP-A but not BSA control. However, it should be noted that there was 
an overall recruitment of macrophages into the FRT due to N-9 treatment prior to viral challenge 
which was independent of HPV (Figure 4B, upper panel). It is a well-known phenomenon that N-9 
elicits a strong inflammatory response [39]; therefore, we quantified macrophage recruitment into the 
basal epithelium by comparing infectious conditions with SP-A-coated virions with BSA controls 
only. Indeed, quantification of the area occupied by macrophages (normalized to the amount of SP-
A/or BSA-pre-treated virus present) of 10 randomly chosen images further indicated a significant 
increase in macrophage recruitment into the basal epithelium in the presence of SP-A.  
To overcome the limitations of quantifying microscopy images and to further demonstrate 
innate immune cell recognition of HPV16-PsVs complexed with SP-A, we isolated FRT cells from 
naïve C57BL/6 mice, which were then exposed to AF488-conjugated HPV16-PsVs ex vivo over a 0–6 
h time course (Figure 5A). Isolated genital cells were analyzed for eosinophils, neutrophils, 
monocytes, and macrophages by multi-color flow cytometry. Innate cell gating is outlined in 
Supplement Figure S1 (Appendix A). While the number of these innate immune cell populations did 
not change dependent on SP-A over time (Figure 5C), co-localization with AF488-conjugated HPV16-
PsVs significantly increased in the presence of SP-A for all studied innate cell populations (Figure 
5D). This is exemplified for the 2 h time point in Figure 5B.   
In summary, we conclude that the SP-A mediated uptake of HPV16-PsVs by various innate 
immune cell populations impairs the overall establishment of infection.  
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Figure 4. SP-A reduces HPV16-PsVs infection in C57BL/6 mice by increasing macrophage recruitment 
into the basal epithelium. 6–10 weeks old female wildtype C57BL/6 mice were pre-treated as 
described in Figure 3A. (A) HPV16-PsVs encapsidating the Gaussia luciferase reporter plasmid 
pGLuc were pre-incubated with a 10-fold (w/w) excess of purified SP-A protein (or BSA control) for 
1 h at room temperature, before intravaginal inoculation. Genital tracts were washed with 2× 50 µl 
PBS at 24 h, 48 h, and 72 h post infection, and activity of the secreted Gaussia luciferase in the vaginal 
lavage fluid as a measure for infection was determined. Data of three independent experiments are 
presented relative to infectivity of the BSA control group at 72 h which was set as 100%. Statistical 
significance was determined using one-way ANOVA and Bonferroni’s multiple comparison tests for 
the individual time points. *= p < 0.05. Bars depict mean values, with error bars showing SEM. (B) 
Mice were treated with N-9 for 6 h as required for HPV challenge (Figure 3A) or left untreated (upper 
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panel). AF488 labelled HPV16-PsVs were pre-incubated with 10-fold (w/w) excess of purified SP-A 
protein (or BSA control) for 1 h at room temperature, before intravaginal inoculation (lower panel) or 
left uninfected (upper panel). Genital tracts were dissected 2 h post infection where indicated, 
embedded in OCT and cryosectioned, followed by staining for nuclei (Hoechst) and macrophages 
(F4/80). Representative confocal images of epithelial tissue (blue) exposed to fluorescent virions 
(green) is shown with staining for macrophages in red. The basal epithelium is outlined in yellow. (C) 
The area of F4/80 staining in the basal layer of the epithelium (outlined) of 10 randomly chosen images 
was quantified by setting the lower and upper thresholds at 18 and 256, respectively, to remove any 
background signal. Macrophage recruitment to the epithelium in response to SP-A coated HPV16-
PsVs was compared to the BSA control group. Statistical significance was determined using a Mann-
Whitney test. *= p < 0.05. Bars depict mean values, with error bars showing SEM. 
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Figure 5. Ex vivo infection of FRT single cell suspension with HPV16-PsVs pre-treated with SP-A 
leads to increased viral uptake by selected immune cell populations. (A) 6–10 weeks old female 
wildtype C57/BL6 mice were treated with Depo-Provera (s.c.) for four days, and then pre-treated with 
N-9 for 6 h. Mice were killed and FRTs dissected for the preparation of single cell suspensions. Cells 
were infected with AF488-labelled HPV16-PsVs that had been preincubated with BSA (control) or SP-
A in a ratio of 1:10 (w/w) for 1 h at room temperature. At the indicated time points, cells were stained 
to visualize and gate the following immune cell populations by flow cytometry: eosinophils 
(CD11b+/SiglecF+/SSChigh), neutrophils (CD11b+/Gr-1high), inflammatory monocytes (CD11b+/Gr-1 
intermediate), and macrophages (CD11b+/F4/80+). (B) Representative flow gates of AF488-labelled HPV16-
PsVs uptake/co-localisation by innate genital cells at the 2 h time point are shown. (C) Shown is the 
percentage of the indicated immune cell populations over time upon infection with HPV16-PsVs pre-
incubated with BSA (control) or SP-A. Pooled data of two independent experiments are presented. 
(D) Shown is the uptake of HPV16-PsVs with the indicated immune cell populations over time 
dependent on pre-incubation of the viral particles with BSA (control) or SP-A. Pooled data of two 
independent experiments are presented. Significances were calculated by means of two-way ANOVA 
and Bonferroni’s multiple comparison tests for the individual time points, with * = p < 0.05; ** = p < 
0.01; *** = p < 0.001. Depicted are mean values, with error bars showing SEM. 
3. Discussion 
As multifunctional host defense collectins, surfactant proteins A and D act as a pattern 
recognition receptors, identifying and binding to invading pathogens via their signature pathogen-
associated molecular patterns, leading to opsonization, recruitment and activation of innate immune 
cells, enhanced phagocytosis (by increasing cell-surface expression of receptors involved in 
phagocytosis), and killing via oxidative mechanisms [27]. SP-A and SP-D therefore function as a first 
line of defense against invading pathogens before the development of specific antimicrobial humoral 
responses. 
While diverse respiratory pathogens have been shown to be controlled by SP-A and SP-D, recent 
reports suggested a protective role of these proteins at non-pulmonary sites such as the FRT [23]. We 
therefore set out to determine whether HPV, the most common sexually transmitted virus, is 
recognized and modulated by SP-A and/or SP-D. We demonstrated by biochemical pull-down 
experiments that SP-A (and to a much lesser extent SP-D) bound directly to HPV16-PsVs. It is 
important to note, however, that the native SP-A protein used for these assays consisted of six trimeric 
units (hence has 18 binding sites per oligomerised molecule and a potentially high avidity) while the 
recombinant trimeric fragment of SP-D consisted only of three binding sites and has therefore 
potentially lower avidity. The involvement of SP-D in HPV binding should therefore be investigated 
in the future with the native protein. 
Consequently, only binding to SP-A had functional consequences for enhanced immune cell 
recognition as demonstrated by increased viral uptake into RAW264.7 murine macrophages. Similar 
observations have been reported for other pathogens found in the reproductive tract: artificial 
supplementation with SP-A protein increased phagocytosis of Ureaplasma by RAW264.7 murine 
macrophages [40] and Chlamydia by THP-1 human macrophages [41]. 
SPs are known to exert their function in a calcium-dependent manner, and crystallographic and 
solution binding studies have elucidated SP-A’s calcium-binding sites, with one being located in the 
CRD, whilst another site is located in an anionic portion of the neck region [42]. We confirmed a 
calcium-dependent increase of HPV16-PsVs uptake into RAW264.7 murine macrophages in the 
presence of SP-A and hypothesize that the calcium binding site in the neck region is important in this 
context as the lectin-binding domain in the CRD seems to not be involved in binding and increased 
viral internalisation as revealed by competition studies using mannose. This is in stark contrast to SP-
A’s mode of binding to HIV, for example: here, SP-A has been reported to bind to HIV’s envelope 
glycoprotein gp120 via its CRD in a calcium-dependent manner that is inhibitable by mannose and 
EDTA [32]. The untypical C-type lectin activity of SP-A in the context of HPV16-PsVs is not surprising 
as HPV is a non-enveloped virus consisting of a protein capsid not known to display glycosylated 
surface/capsid proteins. SP-A may instead recognize HPV16-PsVs in an alternate manner, such as via 
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the neck domain. Current work in our laboratory focuses on the identification of the specific ligand 
binding site on HPV16-PsVs. 
To assess the impact of SP-A during the early events of sexual HPV transmission, we studied 
infection in a murine cervicovaginal challenge model using wildtype C57BL/6 mice. Although SP-A 
has been reported to be expressed in the human vaginal mucosa and vaginal lavage fluid [30], to our 
surprise SP-A was not detected in the murine FRT, neither with nor without HPV16-PsVs challenge. 
This is opposed to the murine urinary tract where the presence of SP-A has recently been described 
[43]. While SP-D has been reported to be expressed in the murine FRT [44], to our knowledge, no 
studies on SP-A in this compartment have been published yet.  
The absence of SP-A in the murine FRT allowed us to study the effect of artificial 
supplementation with exogenous SP-A on HPV16-PsVs challenge. Pre-incubation of the virions with 
a 10-fold excess (w/w) human SP-A protein led to an overall decrease in HPV16-PsVs infection, 
possibly due to increased SP-A-mediated immune cell recognition and elimination of infectious 
virions. Indeed, by confocal microscopy we observed an increased amount of macrophages at the site 
of infection in the presence of SP-A. Similar results have recently been reported for uropathogenic 
Escherichia coli: supplementation with SP-A (but not SP-D) resulted in decreased bacterial growth in 
the murine urinary tract, concurrent with a considerable number of infiltrated immune cells [43].  
To study selected innate immune cell populations for their ability to take up HPV16-PsVs in the 
presence or absence of SP-A, single cell suspensions prepared from murine FRT tissue were analyzed 
by flow cytometry over a time course of 6 h. All assessed populations, i.e. eosinophils, neutrophils, 
monocytes, and macrophages displayed strong SP-A-mediated viral uptake compared to control, 
with neutrophils being the most significant cellular responders to HPV16-PsVs infection in the 
presence of SP-A. 
Based on our murine model, these data suggest an SP-A-mediated opsonization of incoming 
HPV16-PsVs, increased phagocytosis and killing by innate immune cells with an overall effect on 
dampening the infection. Besides enhanced phagocytosis, SPs are also known to aggregate pathogens 
thereby hindering their entry into host cells. Although we did not study this effect, the inhibitory 
effect of SP-A is not necessarily dependent on agglutination [43], and our data strongly point toward 
SP-A-mediated innate immune cell uptake of the virions. While we demonstrated direct biochemical 
interaction between HPV16-PsVs and SP-A, suggesting opsonization as causal basis for enhanced 
phagocytosis, we cannot exclude that the mere presence of exogenously supplied SP-A in the murine 
FRT contributed to enhanced infiltration of innate immune cells to the site of infection and their 
prompt clearance of the invading viral particles.   
Our findings provide a strong basis that encourage further studies into possible broad-spectrum 
activities of SP-A in the prevention of initial oncogenic HPV infection and/or viral shedding in the 
genital tract. While this study focused on HPV type 16, the most common oncogenic HPV type 
worldwide [2], it is likely that SP-A also recognizes other HPV types, both low-risk and high-risk. 
Indeed, innate immune molecules, such as opsonins, generally have a broad range of pathogen 
recognition and therefore could potentially be protective not only against HPV but also other sexually 
transmitted pathogens. For example, SP-A was shown to bind to HIV, thereby protecting CD4+ cells 
from direct infection [32]. However, SP-A plays a dual role in this scenario as it enhances dendritic 
cell-mediated transfer of HIV in vitro [32]. Studies on the role of SPs during pregnancy suggested 
that SP-A and SP-D had a protective function in the murine decidua; and it was proposed that 
exogenous administration of SP-A (and SP-D) could potentially control infection during spontaneous 
term labor and infection-induced preterm labor [45]. 
While our study showed no endogenous SP-A expression in the murine FRT, SP-A has 
previously been detected in the human vaginal mucosal tissue [30]. However, the amount of SP-A 
detected was substantially less than what is typically found in the lung where SP-A is well known to 
play an important role in innate immune defence. It is therefore not clear whether the amount of SP-
A in the human FRT is sufficient to have an impact on efficient pathogen recognition. Since HPV is 
known to efficiently evade innate immune recognition and infect its host relatively “unrecognized”, 
it can be assumed that natural endogenous levels of SP-A do not substantially affect HPV infection 
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in humans and that SP-A levels comparable to the lung are needed for efficient virus elimination. 
This might possibly explain why respiratory HPV infection is a very rare condition [46], although no 
studies investigating the association between SP-A levels and pulmonary HPV infection in patient 
with recurrent respiratory papillomatosis have been conducted to our knowledge. 
In summary, this study assigned a novel role for SP-A in the protection against HPV16-PsVs 
infection in the murine FRT. Future research aims to develop this molecule into a topical microbicide 
as an alternative and potentially broad-spectrum means to current prophylactic HPV vaccination. 
4. Materials and Methods  
4.1. Cell Culture.  
The murine leukemic macrophage cell line RAW264.7 (ATCC® #TIB-71™), the human epithelial 
cervical adenocarcinoma cell line HeLa (ATCC® #CCL-2™) and the virus packaging cell line 
HEK293TT (established from primary embryonal human kidney cells transformed with modified 
human adenovirus) [47] were grown and maintained in DMEM (Life Technologies, Carlsbad, CA, 
USA) supplemented with 10% heat-inactivated fetal calf serum (Biochrom, Cambridge, UK), 100 
U/ml penicillin and 100µg/ml streptomycin (complete DMEM). All cells were grown at 37 °C in 5% 
CO2/95% air humidified atmosphere. 
4.2. Purification of Native Human SP-A and Recombinant SP-D Proteins.  
Human SP-A was purified from bronchoalveolar lavage fluid (BAL) from human patients with 
alveolar proteinosis using a butanol extraction method, as previously described [48]. The BAL was 
collected from patients with informed consent and the necessary ethical permission (the Royal 
Brompton and Harefield Research Ethics Committee NRES10/H0504/9). The patients underwent the 
procedure for therapeutic purposes. The recombinant fragment of human SP-D (rfhSP-D), a 
recombinant trimeric neck/CRD fragment of SP-D, including a short region of the collagen stalk (8 
Gly-X-Y) and representing residues 179 to 355, was purified using a bacterial expression system as 
previously described [49]. The purified rfhSP-D protein was treated for endotoxin by addition of 
1/5th of the protein sample volume of pre-washed Polymyxin B-Agarose beads according to 
manufactures protocol (Merck, Kenilworth, NJ, USA). Levels of endotoxin in the purified SP-A and 
rfhSP-D protein preparation was determined using a Limulus Amebocyte Lysate (LAL) chromogenic 
assay (Lonza, Basel, Seitzerland). An endotoxin level of 10 pg/µg of rfhSP-D protein was judged 
acceptable for use in cell based assays as described previously [33]. The butanol extracted SP-A had 
low endotoxin levels (<1 pg/µg) and was not endotoxin treated. The treated proteins were filtered 
using a 0.22 µm filter and stored as aliquots at −20 °C until usage.  
4.3. HPV16 Pseudovirion Preparation, Viral Internalisation and Infection Assays.  
HPV16-PsVs encapsidating either the intracellularly expressed firefly luciferase reporter gene 
plasmid pGL3-control (Promega, Madison, WI, USA) or the secreted Gaussia luciferase reporter gene 
plasmid pCMV-GLuc2 (New England Biolabs, Ipswich, MA, USA) were produced in 293TT cells by 
co-transfection with the plasmid pXULL which encodes codon-optimised HPV16 L1 and L2 
following published procedures and quality controls [47,50]. Where indicated, the virions were 
labelled with Alexa Fluor® 488 succinimidyl ester (AF488, Life Technologies, Carlsbad, CA, USA) 
before purification by CsCl density gradient centrifugation as described [51].  
For viral internalisation studies, RAW264.7 cells were seeded in 6-well plates at a density of 5 × 
105 cells per well and grown overnight. AF488-labelled HPV16-PsVs were incubated with purified 
human SP-A or recombinant SP-D protein or BSA (Sigma, St. Louis, MO, USA) at a w/w ratio of 1:10 
for 1 h at room temperature before addition to the cells at a final viral density of approximately 4 
pg/cell for 1 h at 37 °C. Where indicated, SP-A was preincubated with increasing mannose 
concentrations (20–200 mM) or 2 mM and 5 mM CaCl2 (with or without 10 mM EDTA) for 1 h at 37 
°C before addition of the virions. Cells were rinsed with PBS and harvested with 0.025% 
trypsin/0.01% EDTA in PBS to remove surface-bound virions, thereby allowing detection of 
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internalized AF488-labelled viral particles by flow cytometry [50]. Cells were washed in FACS wash 
solution (0.5% BSA in PBS) and fixed with 1% (v/v) formaldehyde (Sigma) in PBS. The detection of 
AF488-positive cells was performed using a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, 
USA) together with the software CellQuest Pro. Quadrant statistics of three independent experiments 
performed in triplicate were used to calculate the means ± SEM.  
For infection studies, reporter gene expression was determined. RAW264.7 or HeLa cells were 
seeded in 12-well plates at a density of 1 × 105 or 5 × 104, respectively, cells per well and grown 
overnight. HPV16-PsVs encapsidating the plasmid pGL3-control were incubated with purified 
human SP-A protein or BSA at a w/w ratio of 1:10 for 1h at room temperature before addition to the 
cells at a final viral density of approximately 2 pg/cell at 37 °C for 48 h. Cells were washed with PBS, 
harvested and luciferase activity measured using the Luciferase Assay System kit (Promega) with the 
Fluoroscan Ascent FL (Thermo Fisher Scientific, Waltham, MA, USA). Raw luciferase data were 
normalised against total protein concentration of the lysates determined with the Pierce™ BCA 
Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). Three independent experiments were 
performed in triplicate and used to calculate the means ± SEM. 
For all internalization and infection experiments, one-way ANOVA and Tukey post-hoc tests 
were used for determination of statistical significance compared to controls. 
4.4. Co-Immunoprecipitation and Western Blotting.  
To biochemically determine whether SP-A and/or SP-D interact with HPV16-PsVs, Co-IP 
experiments were performed by incubating either 5µg purified human SP-A or human SP-D with 0.2 
µg HPV16-PsVs (or alone as a control) in complete DMEM for 1 h at 4 °C. Lysis/Wash Buffer (Thermo 
Scientific) was added to bring each solution’s total volume to 150µL. 5µl of each “input” samples 
were kept aside for analysis. 2.5 µg antibody (either CamVir1 against HPV16-L1 (Abcam, Cambridge, 
UK), mouse anti-human SP-A (Hyb 238-04, ThermoFisher (Waltham, MA, USA)) or rabbit anti-
human SP-D [33] was then added to the appropriate samples and incubated overnight at 4 °C 
rotating. 25 µl Protein G Sepharose beads (Sigma) were added to each reaction, and tubes were 
incubated for 2 h at 4 °C rotating. Samples were added to spin columns (Thermo Scientific), and flow 
through (FT) collected by centrifugation at 1000 g for 1 min. Samples were washed three times with 
200 µl Lysis/Wash Buffer, once with 100 µl 1× Conditioning Buffer (Thermo Scientific) and eluted 
with a total of 40 µl Elution Buffer (Thermo Scientific). Input, FT (3 µl each) and eluate samples (20 
µl) were analysed by reduced SDS-PAGE followed by Western Blotting according to conventional 
protocols. Proteins were detected using the CamVir1 primary antibody in a 1:2500 dilution together 
with a goat-anti-mouse secondary antibody conjugated to horseradish peroxidase (HRP) (Bio-Rad, 
Hercules, CA, USA) in a 1:5000 dilution. 
For detection of SP-A in mouse tissues, a rabbit anti-mouse SP-A antibody raised again a 
recombinant fragment of mouse SP-A was used at a 1:1000 dilution, followed by an anti-rabbit HRP 
secondary antibody (Jackson Laboratories, Bar Harbor, ME, USA). 
All Western blots were visualised using the Lumi-Glo chemiluminescent substrate (KPL 
(seracare), Milford, MA, USA) together with a Biospectrum™ 500 Imaging System (Ultra Violet 
Products, UVP, Mile End South, SA, Australia). 
4.5. HPV16-PsVs Murine Cervicovaginal Challenge Model.  
In order to recapitulate the early events of human sexual HPV transmission, a murine genital 
challenge model was applied as described before [8,37] (Figure 3A). Briefly, 4 days prior HPV 
infection, 6–10 weeks old C57BL/6 mice were treated systemically with progesterone by sub-
cutaneous injection of 2 mg/20 g Depo-Provera (Pfizer) suspended in 200 µl PBS in order to 
equilibrate hormonal levels and facilitate infection of sexually transmitted diseases by prolonged 
diestrus [52]. 6 h prior HPV infection, mice were lightly anaesthetized by intra-peritoneal injection of 
125 µl ketamine (1.5 mg/20 g) and xylazine (0.2 mg/20 g) and intravaginally received 25 µl of 4% 
Nonoxynol-9 (N-9) (abcam) in a formulation of 3% carboxymethylcellulose (CMC) in order to 
chemically disrupt the genital epithelial and to promote HPV infection [8]. For HPV infections, mice 
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were again lightly anaesthetized and intravaginally inoculated with 1 µg HPV16-PsVs encapsidating 
the plasmid pCMV-GLuc2 or 3 µg virus encapsidating the plasmid pGL3-control in a total volume of 
20 µl in the presence of 3% CMC formulation. Where indicated, viral particles were incubated with 
purified human SP-A protein or BSA at a w/w ratio of 1:10 for 1 h at room temperature before addition 
of CMC and intravaginal administration. Vaginal lavages were performed at 24 h, 48 h, and 72 h as 
indicated by rinsing the genital tract with 2× 50 µl sterile PBS. Cells and debris were removed by 
centrifugation and the remaining supernatants were analyzed for secreted Gaussia luciferase 
expression as a measure for infection using the Gaussia Luciferase Assay Kit (New England Biolabs) 
with the Fluoroscan Ascent FL (Thermo Fisher Scientific). Where indicated, mice were killed 24 h or 
72 h post infection using halothane inhalation, and FRTs (excluding uterine horns and ovaries) were 
excised, snap frozen in liquid nitrogen and homogenised on ice in the presence of 500 µl 1× Cell 
Culture Lysis Reagent (Promega) or in the presence of 500 µl TRIzol™ reagent (Life Technologies) 
for further protein or gene expression analyses, respectively.  
All animal work was approved by the Faculty of Health Sciences Animal Ethics Committee, 
University of Cape Town (AEC 016/008). 
4.6. Gene Expression Analysis.  
RNA was extracted from uninfected murine tissue (lung and FRT) and HPV16-PsVs challenged 
murine tissue (FRT) and reverse transcribed using the High-Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems™, Foster City, CA, USA). Briefly, 1 µg total RNA was added to 0.8 µl 100 
mM dNTP mix, 2 µl 10× RT Random Primers, 2 µl 10× RT Buffer, 1 µl MultiScribe™ Reverse 
Transcriptase (50 U/µL) and 1 µl RNase Inhibitor in a total volume of 20 µl. cDNA synthesis was 
performed by incubating the samples for 10 min at 25 °C, followed by 120 min at 37 °C and a final 5 
min 85 °C denaturation. The cDNA was then used in subsequent PCRs to determine expression of 
SP-A, pGL3-control and GAPDH using the following primer pairs: SP-A forw 
ACCTGGATGAGGAGCTTAGACTGC and SP-A rev TGCTTGCGATGGCCTCGTTCT; pGL3 forw 
CGGGCGCGGTCGGTAAAGT and pGL3 rev AACAACGGCGGCGGGAAGT; GAPDH forw 
CCAATGTGTCCGTCGTGGATCT and GAPDH rev GTTGAAGTCGCAGGAGACAACC. Each 
reaction mixture contained 2.5 µl 10× DreamTaq Buffer (Fermentas, Waltham, MA, USA), 1 µl 10 µM 
forward primer, 1 µl 10 µM reverse primer, 1 µl 10 µM dNTP mix, 1 U DreamTaq (Fermentas) and 1 
µl cDNA in a total volume of 25 µl, and was performed under the following conditions: 3 min 95 °C, 
35 cycles (30 s 95 °C, 30 s 60 °C, 30 s 72 °C), 5 min 72 °C. PCR products were visualized by agarose 
gel electrophoresis. 
4.7. Immunohistochemistry.  
To visualize macrophages and viral particles by immunohistochemistry (IHC), FRTs dissected 
from AF488-HPV16-PsVs (preincubated with BSA or SP-A) infected mice were prepared for 
cryosectioning. Briefly, tissues were fixed in 4% paraformaldehyde for 1 h, washed 3 × 10 min with 
PBS and suspended in 30% sucrose overnight at 4 °C. Tissues were embedded in Optimal Cutting 
Temperature (OCT, Sakura Finetec, Torrance, CA, USA) compound in a plastic mould (Sakura 
Finetec, Torrance, CA, USA) and frozen over dry ice. Tissue sections of 20 µm were cut using a Leica 
CM1850 cryostat, adhered to microscope slides coated with 3-Aminopropyltriethoxysilane (APES) 
and air dried overnight. For IHC staining, sections were fixed and permeabilised in methanol for 10 
min at −20 °C, washed 3 × 10 min with PBS and blocked in 1% BSA for 1 h at room temperature. 
Macrophages were stained with a rat anti-mouse F4/80 antibody (CI:A3-1, Thermo Scientific) at a 
dilution of 1:1000 in 1% BSA blocking solution overnight at 4 °C in a sealed humidified chamber. 
Sections were washed 3 × 10 min with PBS and incubated with a goat anti-rat AF555 secondary 
antibody (Invitrogen, Carlsbad, CA, USA) at a 1:500 dilution in 1% BSA blocking solution for 90 min 
at room temperature. Following 3 × 10 min washes with PBS, sections were counterstained with 0.5 
µg/ml Hoechst Nuclear Stain (Sigma) for 10 min at room temperature, washed in PBS, and mounted 
on glass slides with Mowiol (Sigma). Slides were visualized using a Zeiss LSM880 Airyscan confocal 
microscope together with Zen 2.3 SP1 software (Zeiss, Oberkochen, Germany). Epithelial structure 
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was determined using the transmitted light and Hoechst channels only to eliminate bias. For 
quantification of macrophage recruitment, ten such areas were randomly selected for each condition, 
and Z-stacks were taken with the Hoechst, AF488 and AF555 channels selected. Z-stack dimensions 
were then normalised to 18 optical sections per image stack, and maximum intensity projections were 
done. The area occupied by macrophages (positive for F4/80) in the epithelium was determined by 
outlining the basal epithelium in each maximum intensity projection and determining the area 
occupied by the AF555 stain in these selected regions. This was normalized to the area occupied by 
the AF488-conjugated HPV16-PsVs, as the number of pseudovirions surrounding the basal 
epithelium is predicted to impact the level of immune response, i.e. the number of macrophages that 
are recruited to the basal epithelium. Normalizing was done for each individual maximum intensity 
projection as follows: 
𝐴𝐹555 (µm x µm)
𝐴𝐹488 (µm x µm)  𝑋 100 
The lower and upper thresholds were set at 18 and 256 greyscale levels, respectively, for each 
maximum intensity projection to remove background signal so that the measured signal for AF555 
corresponded to the area representing F4/80 macrophage staining.  
4.8. Flow Cytometry Analysis of Genital Tract Immune Cell Populations.  
In order to prepare single cell suspensions, FRTs of uninfected mice was removed 6 h post N-9 
treatment (Figure 5A), finely cut and digested in complete DMEM containing 1% HEPES and 20 
µg/ml Liberase™ TL (Roche, Basel, Switzerland), for 1 h at 37 °C with gentle shaking. Digested tissue 
was passed through a 70 µm cell strainer and resuspended in fresh complete DMEM. Single cell 
suspensions were counted by trypan blue exclusion, using a haemocytometer slide and resuspended 
at a concentration of 1 × 107 cells/ml. For time course experiments, 1 × 106 cells were infected at 37 °C, 
5% CO2 for 30 min to 6 h with 1 µg AF488-conjugated HPV16-PsVs which had been pre-incubated 
with purified human SP-A protein or BSA at a w/w ratio of 1:10 for 1 h at room temperature. At the 
indicated time points, innate immune cell populations were analysed by multi-colour flow 
cytometry. The following fluorochrome-conjugated antibodies were used: CD45 Alexa Fluor 700 
(Biolegend, Clone: 30-F11, San Diego, CA, USA), CD11b Brilliant Violet (BV) 421™ (Biolegend, Clone: 
M1/70), SigLecF PE (Biolegend, Clone: S17007L), Gr-1 (Ly-6G+Ly-6C) APC Cy7 (eBioscience, Clone: 
RB6-8C5, San Diego, CA, USA), F4/80 BV605 (Biolegend, Clone: BM8). Cells were stained in staining 
buffer (0.5% BSA, 2 mM EDTA in PBS) for 20 min at 4 °C (dark), washed and resuspended in staining 
buffer for acquisition using the BD LSR Fortessa. Data was analysed using FlowJo software (V10). 
Innate immune cell populations were identified as CD45+CD11b+/SigLecF+/SSChigh (eosinophils), 
CD45+CD11b+/Gr-1high (neutrophils), CD45+CD11b+/Gr-1intermediate (monocytes) and 
CD45+CD11b+/F4/80+ (macrophages) (Appendix A, Supplementary Figure S1). Uptake of internalized 
AF488-labelled virions by immune cells were defined as AF488+ cells, based on fluorescence minus 
one (FMO) controls.   
5. Conclusions 
This study is the first to demonstrate that SP-A but not SP-D binds directly to HPV16-PsVs and 
increases viral uptake into innate immune cells. This enhanced immune recognition leads to an 
overall decrease of cervicovaginal HPV infection in a murine model. The potentially protective 
functions of SP-A for genital HPV infection hold great promise for the development topical 
microbicides as alternative means against new HPV infections. 
6. Patents 
A patent application has been filed and is currently at PCT stage, pending national phase entry. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: HPV+SP-A 
ex vivo infection: Innate cell gating strategy. 
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Appendix A 
 
Figure A1. HPV+SP-A ex vivo infection: Innate cell gating strategy. Hormone-synchronised 6–10 
weeks old female wildtype C57/BL6 mice were pre-treated with N-9 for 6 h. Thereafter, mice were 
killed and the FRTs dissected for the preparation of single cell suspensions. Cells were infected with 
AF488-labelled HPV16-PsVs that had been preincubated with BSA (control) or SP-A in a ratio of 1:10 
(w/w) for 1 h at room temperature. At various time points, cells were stained to visualise and gate the 
following innate immune cell populations by flow cytometry: eosinophils (CD11b+/SiglecF+/SSChigh), 
neutrophils (CD11b+/Gr-1high), inflammatory monocytes (CD11b+/Gr-1intermediate), and macrophages 
(CD11b+/F4/80+). AF488-labelled HPV16-PsVs uptake/co-localisation by innate genital cells were 
gated as AF488+ innate cells, based on FMO (uninfected) controls. 
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